CASI Pharmaceuticals Inc (CASI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has a cash flow conversion efficiency ratio of -0.014x as of March 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-843.00K) by net assets ($62.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CASI Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
CASI Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CASI operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CASI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tartana Minerals Ltd
AU:TAT
|
-0.217x |
|
MEMPHASYS LTD
F:IG7
|
N/A |
|
Accord Financial Corp.
TO:ACD
|
1.083x |
|
Benjamin Hornigold Ltd
AU:BHD
|
0.006x |
|
Winshear Gold Corp
V:WINS
|
-1.401x |
|
Alliance Pharma plc
LSE:APH
|
0.099x |
|
Cemtrex Inc
NASDAQ:CETX
|
-0.127x |
|
PREMIER AFRICAN MINERALS
F:0PA
|
N/A |
Annual Cash Flow Conversion Efficiency for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual cash flow conversion efficiency of CASI Pharmaceuticals Inc from 1994 to 2024. For the full company profile with market capitalisation and key ratios, see CASI Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.85 Million | $-29.22 Million | -15.788x | -1810.76% |
| 2023-12-31 | $24.16 Million | $-19.97 Million | -0.826x | -162.26% |
| 2022-12-31 | $66.93 Million | $-21.09 Million | -0.315x | -26.72% |
| 2021-12-31 | $107.96 Million | $-26.84 Million | -0.249x | +0.52% |
| 2020-12-31 | $103.57 Million | $-25.89 Million | -0.250x | -0.72% |
| 2019-12-31 | $93.67 Million | $-23.24 Million | -0.248x | +4.97% |
| 2018-12-31 | $109.46 Million | $-28.58 Million | -0.261x | -57.19% |
| 2017-12-31 | $38.54 Million | $-6.40 Million | -0.166x | +42.68% |
| 2016-12-31 | $20.78 Million | $-6.02 Million | -0.290x | -132.00% |
| 2015-12-31 | $-6.09 Million | $-5.51 Million | 0.906x | -90.43% |
| 2014-12-31 | $-422.21K | $-4.00 Million | 9.463x | +4416.67% |
| 2013-12-31 | $14.94 Million | $-3.28 Million | -0.219x | +18.39% |
| 2012-12-31 | $8.24 Million | $-2.21 Million | -0.269x | +84.08% |
| 2011-12-31 | $2.53 Million | $-4.27 Million | -1.687x | -81.46% |
| 2010-12-31 | $5.33 Million | $-4.96 Million | -0.930x | -117.54% |
| 2009-12-31 | $-1.93 Million | $-10.21 Million | 5.303x | +251.61% |
| 2008-12-31 | $5.92 Million | $-20.71 Million | -3.498x | -299.91% |
| 2007-12-31 | $26.90 Million | $-23.52 Million | -0.875x | -97.78% |
| 2006-12-31 | $46.98 Million | $-20.77 Million | -0.442x | +10.49% |
| 2005-12-31 | $29.39 Million | $-14.52 Million | -0.494x | -7.57% |
| 2004-12-31 | $35.72 Million | $-16.41 Million | -0.459x | +33.95% |
| 2003-12-31 | $34.88 Million | $-24.25 Million | -0.695x | +83.95% |
| 2002-12-31 | $10.51 Million | $-45.53 Million | -4.332x | -90.19% |
| 2001-12-31 | $23.21 Million | $-52.87 Million | -2.278x | +1.89% |
| 2000-12-31 | $19.06 Million | $-44.25 Million | -2.322x | -42.68% |
| 1999-12-31 | $22.00 Million | $-35.80 Million | -1.627x | -332.20% |
| 1998-12-31 | $33.20 Million | $-12.50 Million | -0.377x | -140.17% |
| 1997-12-31 | $42.10 Million | $-6.60 Million | -0.157x | -239.90% |
| 1996-12-31 | $47.70 Million | $-2.20 Million | -0.046x | +96.26% |
| 1995-12-31 | $3.60 Million | $-4.44 Million | -1.233x | +94.33% |
| 1994-12-31 | $200.00K | $-4.35 Million | -21.750x | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more